Meridian Bioscience (NASDAQ: VIVO) reported Q2 EPS of $0.19, $0.03 better than the analyst estimate of $0.16. Revenue for the quarter came in at $50.2 million versus the consensus estimate of $51.74 million.

For earnings history and earnings-related data on Meridian Bioscience (VIVO) click here.